Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ), Zealand Pharma (OtherZLDPF) and Camurus AB (OtherCAMRF)

Tipranks - Tipranks - Fri Apr 17, 7:35AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ), Zealand Pharma (ZLDPF) and Camurus AB (CAMRF).

Claim 30% Off TipRanks

Johnson & Johnson (JNJ)

J.P. Morgan analyst Chris Schott maintained a Hold rating on Johnson & Johnson yesterday and set a price target of $260.00. The company’s shares closed last Wednesday at $238.67.

According to TipRanks.com, Schott is a 4-star analyst with an average return of 4.8% and a 55.1% success rate. Schott covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals, Bristol-Myers Squibb, and Elanco Animal Health. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Johnson & Johnson with a $261.43 average price target, implying an 9.0% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Hold rating on the stock with a $254.00 price target.

See the top stocks recommended by analysts >>

Zealand Pharma (ZLDPF)

Jefferies analyst Benjamin Jackson CFA maintained a Buy rating on Zealand Pharma today and set a price target of DKK505.00. The company’s shares closed last Friday at $45.63.

According to TipRanks.com, CFA is ranked #3689 out of 12196 analysts.

Currently, the analyst consensus on Zealand Pharma is a Moderate Buy with an average price target of $78.52.

Camurus AB (CAMRF)

In a report released today, Shan Hama from Jefferies maintained a Buy rating on Camurus AB, with a price target of SEK700.00. The company’s shares closed last Friday at $55.00.

Hama has an average return of 1.4% when recommending Camurus AB. ;'>

According to TipRanks.com, Hama is ranked #8154 out of 12196 analysts.

Currently, the analyst consensus on Camurus AB is a Moderate Buy with an average price target of $76.52, representing a 39.1% upside. In a report issued on April 1, TipRanks – OpenAI also reiterated a Buy rating on the stock with a SEK517.00 price target.

Read More on JNJ:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).